Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;34(2):902-908.
doi: 10.1111/jvim.15747. Epub 2020 Feb 26.

Blood glucose and insulin concentrations after alpha-2-agonists administration in horses with and without insulin dysregulation

Janice E Kritchevsky  1 , Genevieve S Muir  2 , Dakota H Z Leschke  2 , Jack K Hodgson  2 , Emily K Hess  1 , Francois-Rene Bertin  2
Affiliations

Blood glucose and insulin concentrations after alpha-2-agonists administration in horses with and without insulin dysregulation

Janice E Kritchevsky et al. J Vet Intern Med. 2020 Mar.

Abstract

Background: In metabolically stable horses, alpha-2-agonists suppress insulin secretion with transient hyperglycemia and rebound hyperinsulinemia. In horses with insulin dysregulation (ID), the effect of alpha-2-agonists has not been investigated; however, both the alpha-2-agonist-induced suppression of insulin secretion and rebound hyperinsulinemia could have clinical relevance.

Hypothesis/objectives: In horses with ID, alpha-2-agonists will alter insulin and glucose dynamics.

Animals: Seven horses with ID and 7 control horses.

Methods: In this randomized crossover study, xylazine hydrochloride (1.1 mg/kg) or detomidine hydrochloride (30 μg/kg) were administered IV, and blood was collected for glucose and insulin concentrations at 0, 15, 30, 45, 60, 90, 120, 150, 180, and 300 minutes after administration. Horses received each drug in a random order with a 24-hour washout period between drugs. Percent change in glucose and insulin concentrations was compared between groups, drugs, and over time with P < .05 considered significant.

Results: A significant time-dependent effect of both alpha-2-agonists on glucose and insulin concentrations in control and ID horses was identified (P = .01 for all comparisons). There was no significant effect of sedative selection and endocrine status on blood glucose concentration in either group; however, in ID horses, xylazine administration resulted in severe rebound hyperinsulinemia whereas detomidine administration did not (P = .02).

Conclusions and clinical importance: Alpha-2-agonists have a significant effect on glucose and insulin concentrations in horses. In ID horses, detomidine could minimize hyperinsulinemia when compared to xylazine.

Keywords: detomidine; endocrinology; equine; metabolism; pancreas; xylazine.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mean (±SD) glucose concentration (percentage of baseline) after IV administration of xylazine hydrochloride (open circles) and detomidine hydrochloride (black squares) in 7 control horses (solid line, panel A) and 7 insulin dysregulated horses (dashed line, panel B). *P < .05 versus baseline
Figure 2
Figure 2
Mean (± SD) insulin concentration (percentage of baseline) after IV administration of xylazine hydrochloride (open circles) and detomidine hydrochloride (black squares) in 7 control horses (solid line, panel A) and 7 insulin dysregulated horses (dashed line, panel B). *P < .05 versus baseline; †P < .05 xylazine versus detomidine
Figure 3
Figure 3
Mean (±SD) insulin concentration (percentage of baseline) after IV administration of xylazine hydrochloride (open circles, panel A) and detomidine hydrochloride (black squares, panel B) in 7 control horses (solid line) and 7 insulin dysregulated horses (dashed line). *P < .05 versus baseline. To facilitate the reader's evaluation, insulin data are presented per group (Figure 2) and drug (Figure 3)
See this image and copyright information in PMC

References

    1. Rohrbach H, Korpivaara T, Schatzmann U, Spadavecchia C. Comparison of the effects of the alpha‐2 agonists detomidine, romifidine and xylazine on nociceptive withdrawal reflex and temporal summation in horses. Vet Anaesth Analg. 2009;36:384‐395. - PubMed
    1. England GC, Clarke KW, Goossens L. A comparison of the sedative effects of three alpha 2‐adrenoceptor agonists (romifidine, detomidine and xylazine) in the horse. J Vet Pharmacol Ther. 1992;15:194‐201. - PubMed
    1. Grimsrud KN, Ait‐Oudhia S, Durbin‐Johnson BP, et al. Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis. J Vet Pharmacol Ther. 2015;38:24‐34. - PMC - PubMed
    1. Ringer SK, Schwarzwald CC, Portier K, Mauch J, Ritter A, Bettschart‐Wolfensberger R. Blood glucose, acid‐base and electrolyte changes during loading doses of alpha(2)‐adrenergic agonists followed by constant rate infusions in horses. Vet J. 2013;198:684‐689. - PubMed
    1. Hirose H, Maruyama H, Ito K, Kido K, Koyama K, Saruta T. Effects of alpha 2‐ and beta‐adrenergic agonism on glucagon secretion from perfused pancreata of normal and streptozocin‐induced diabetic rats. Metabolism. 1993;42:1072‐1076. - PubMed

Publication types

Grants and funding